Inhibiting glycogen synthesis prevents lafora disease in a mouse model

Annals of Neurology

Volumn 74, Issue 2, 2013, Pages 297-300

  Pederson, Bartholomew A ^a   Turnbull, Julie ^b   Epp, Jonathan R ^c   Weaver, Staci A ^a   Zhao, Xiaochu ^b   Pencea, Nela ^b,d   Roach, Peter J ^e   Frankland, Paul W ^c   Ackerley, Cameron A ^d   Minassian, Berge A ^b,d  

^a BALL STATE UNIVERSITY   (United States)

^b Program in Genetics and Genome Biology   (United States)

^c Program in Neurosciences and Mental Health   (United States)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOGEN; KAINIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GLIOSIS; GLYCOGEN SYNTHESIS; MOUSE; MYOCLONUS EPILEPSY; NERVE DEGENERATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SEIZURE SUSCEPTIBILITY;

ANIMALS; DISEASE MODELS, ANIMAL; DUAL-SPECIFICITY PHOSPHATASES; GENE KNOCKOUT TECHNIQUES; GLYCOGEN; GLYCOGEN SYNTHASE; LAFORA DISEASE; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT;

EID: 84884894346     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23899     Document Type: Article

References (20)

1. Lafora GR, Glueck B,. Beitrag zur Histopathologie der myoklonischen Epilepsie. Zeitschrift Gesamte Neurologische Psychiatrie 1911; 6: 1-14.
2. Sakai M, Austin J, Witmer F, Trueb L,. Studies in myoclonus epilepsy (Lafora body form). II. Polyglucosans in the systemic deposits of myoclonus epilepsy and in corpora amylacea. Neurology 1970; 20: 160-176.
3. Tiberia E, Turnbull J, Wang T, et al. Increased laforin and laforin binding to glycogen underlie Lafora body formation in malin-deficient Lafora disease. J Biol Chem 2012; 287: 25650-25659.
4. Gentry MS, Worby CA, Dixon JE,. Insights into Lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin. Proc Natl Acad Sci U S A 2005; 102: 8501-8506.
5. Tagliabracci VS, Girard JM, Segvich D, et al. Abnormal metabolism of glycogen phosphate as a cause for Lafora disease. J Biol Chem 2008; 283: 33816-33825.
6. Puri R, Suzuki T, Yamakawa K, Ganesh S,. Hyperphosphorylation and aggregation of Tau in laforin-deficient mice, an animal model for Lafora disease. J Biol Chem 2009; 284: 22657-22663.
7. Rao SN, Maity R, Sharma J, et al. Sequestration of chaperones and proteasome into Lafora bodies and proteasomal dysfunction induced by Lafora disease-associated mutations of malin. Hum Mol Genet 2010; 19: 4726-4734.
8. Sharma J, Mulherkar S, Mukherjee D, Jana NR,. Malin regulates Wnt signaling pathway through degradation of dishevelled2. J Biol Chem 2012; 287: 6830-6839.
9. Sharma J, Rao SN, Shankar SK, et al. Lafora disease ubiquitin ligase malin promotes proteasomal degradation of neuronatin and regulates glycogen synthesis. Neurobiol Dis 2011; 44: 133-141.
10. Fong NM, Jensen TC, Shah AS, et al. Identification of binding sites on protein targeting to glycogen for enzymes of glycogen metabolism. J Biol Chem 2000; 275: 35034-35039.
11. Turnbull J, Depaoli-Roach AA, Zhao X, et al. PTG depletion removes Lafora bodies and rescues the fatal epilepsy of Lafora disease. PLoS Genet 2011; 7: e1002037.
12. Ganesh S, Delgado-Escueta AV, Sakamoto T, et al. Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice. Hum Mol Genet 2002; 11: 1251-1262.
13. Pederson BA, Chen H, Schroeder JM, et al. Abnormal cardiac development in the absence of heart glycogen. Mol Cell Biol 2004; 24: 7179-7187.
14. Pederson BA, Cope CR, Schroeder JM, et al. Exercise capacity of mice genetically lacking muscle glycogen synthase: in mice, muscle glycogen is not essential for exercise. J Biol Chem 2005; 280: 17260-17265.
15. Pederson BA, Schroeder JM, Parker GE, et al. Glucose metabolism in mice lacking muscle glycogen synthase. Diabetes 2005; 54: 3466-3473.
16. Valles-Ortega J, Duran J, Garcia-Rocha M, et al. Neurodegeneration and functional impairments associated with glycogen synthase accumulation in a mouse model of Lafora disease. EMBO Mol Med 2011; 3: 667-681.
17. Racine R, Okujava V, Chipashvili S,. Modification of seizure activity by electrical stimulation. 3. Mechanisms. Electroencephalogr Clin Neurophysiol 1972; 32: 295-299.
18. Weinstein DA, Correia CE, Saunders AC, Wolfsdorf JI,. Hepatic glycogen synthase deficiency: an infrequently recognized cause of ketotic hypoglycemia. Mol Genet Metab 2006; 87: 284-288.
19. Kollberg G, Tulinius M, Gilljam T, et al. Cardiomyopathy and exercise intolerance in muscle glycogen storage disease 0. N Engl J Med 2007; 357: 1507-1514.
20. Ashe KM, Taylor KM, Chu Q, et al. Inhibition of glycogen biosynthesis via mTORC1 suppression as an adjunct therapy for Pompe disease. Mol Genet Metab 2010; 100: 309-315.